| Literature DB >> 35072025 |
Taisto Sarkola1,2, Marita Lipsanen-Nyman3, Hannu Jalanko3, Eero Jokinen1.
Abstract
BACKGROUND: Mulibrey nanism (MUL) is a rare condition with profound growth delay. Congestive heart failure is a major determinant of prognosis. The aim was to delineate pericardial constriction and myocardial functional abnormalities in a pediatric MUL sample.Entities:
Year: 2021 PMID: 35072025 PMCID: PMC8767125 DOI: 10.1016/j.cjco.2021.08.012
Source DB: PubMed Journal: CJC Open ISSN: 2589-790X
Characteristics, anthropometrics, and clinical findings of study subjects at study visit
| Characteristic | MUL patients (n = 23) | Control subjects (n = 23) | |||
|---|---|---|---|---|---|
| Mean or median | SD or range | Mean or median | SD or range | ||
| Male sex, n | 11 | 11 | |||
| Age, y | 10.3 | 1.9–15.2 | 10.0 | 1.2–15.8 | NS |
| Weight, kg | 14.8 | 6.6–47.0 | 33.0 | 13.0–68.7 | < 0.001 |
| Weight-for-age, Z | –5.17 | 2.78 | 0.20 | 0.96 | < 0.001 |
| Weight-for-height, Z | –2.11 | 1.70 | 0.08 | 0.94 | < 0.001 |
| Weight-for-height, % | –13.3 | 8.83 | 0.92 | 12.7 | < 0.001 |
| Height, cm | 110.5 | 69.5–157 | 146.4 | 93–175.5 | < 0.001 |
| Height-for-age, Z | –4.47 | –10.4–1.10 | 0.20 | –3.34–1.85 | < 0.001 |
| Lean body mass | 14.7 | 6.8–36.1 | 29.5 | 11.3 – 46.2 | < 0.001 |
| Waist-to-hip ratio | 0.93 | 0.73–1.23 | 0.85 | 0.71–1.22 | 0.007 |
| Body surface area, m2 | 0.66 | 0.36–1.43 | 1.15 | 0.58–1.78 | < 0.001 |
| Thorax circumference, mm | 508 | 395–790 | 655 | 507–800 | < 0.001 |
| Alanine aminotransferase, U/l | 35 | 19 | NA | ||
| Pro-BNP, ng/l | 385 | 682 | |||
| Estimated jugular venous pressure, mm Hg | 7 | 3 | Veins not observable | ||
| Liver (cm from right costal margin) | 2 | 0–5 | Liver not palpable | ||
| Modified Ross score | 1 | 0–13 | 0 | ||
| Modified Ross class | 1 | 1–3 | 1 | ||
| Systolic BP, mm Hg | 95 | 13 | 104 | 10 | 0.009 |
| Systolic BP, Z | –0.14 | 1.32 | 0.27 | 0.67 | 0.210 |
| Diastolic BP, mm Hg | 58 | 7 | 60 | 7 | 0.405 |
| Diastolic BP, Z | –0.16 | 1.22 | 0.13 | 0.52 | 0.310 |
| Heart rate, bpm | 91 | 20 | 76 | 14 | 0.005 |
Data are presented as mean and standard deviation (SD), median and range, or count and percentage, unless otherwise specified.
BP, blood pressure. bpm, beats per minute; NA, not assessed; NS nonsignificant. pro-BNP, pro-hormone brain natriuretic peptide.
N = 18 for lean body mass for mulibrey nanism (MUL) patients and individually matched control subjects.
Change in cardiac inflows and outflows, interventricular dependence, and inferior vena cava diameter change during peak inspiration, compared with end-expiration
| MUL patients (n = 23) | Control subjects (n = 23) | ||||
|---|---|---|---|---|---|
| Mean or median | SD or range | Mean or median | SD or range | ||
| IVC max diameter, cm | 0.80 | 0.50–1.80 | 1.19 | 0.60–1.86 | 0.063 |
| IVC min diameter, cm | 0.50 | 0.20–1.16 | 0.46 | 0.16–1.12 | 0.466 |
| IVC diameter | –39 | 21 | –59 | 11 | < 0.001 |
| HV S-wave | 50 | –5 – 219 | 69 | 26–189 | 0.162 |
| HV S/D-ratio | –26 | –47–57 | –21 | –64–34 | 0.432 |
| HV A-wave velocity | 37 | –39–269 | 67 | 0–113 | 0.442 |
| A-wave duration | 5 | –36–128 | 36 | –7–165 | 0.011 |
| HV D-wave velocity early expirium, cm/s | 39 | 15 | 42 | 13 | 0.489 |
| HV A-wave velocity early expirium, cm/s | 46 | 15 | 31 | 9 | < 0.001 |
| HV A/D -ratio early expirium | 1.32 | 0.67 | 0.79 | 0.27 | < 0.001 |
| TV E-wave | 58 | 18–156 | 36 | 8–81 | 0.004 |
| TV A-wave | 32 | –26–120 | 8 | –16–66 | 0.166 |
| TV E/A-ratio | 26 | 37 | 25 | 29 | 0.768 |
| Pulmonary artery peak velocity | 16 | 12 | 0 | 4 | < 0.001 |
| PV S-wave | –19 | 28 | 4 | 31 | 0.010 |
| PV D-wave | –20 | 26 | 7 | 17 | < 0.001 |
| MV E-wave | –15 | 9 | 3 | 7 | < 0.001 |
| MV A-wave | –4 | 26 | 21 | 37 | 0.010 |
| MV E/A ratio | –13 | –36–61 | –14 | –43–72 | 0.796 |
| Ascending aorta peak velocity | –7 | 16 | –1 | 3 | 0.033 |
| End expiratory | 0.99 | 0.05 | 1.00 | 0.02 | 0.125 |
| Peak inspiratory | 0.81 | 0.12 | 0.95 | 0.07 | < 0.001 |
| Absolute change | –0.18 | 0.10 | –0.06 | 0.06 | < 0.001 |
| End expiratory | 1.00 | 0.05 | 0.98 | 0.05 | 0.248 |
| Peak inspiratory | 0.98 | 0.05 | 0.99 | 0.03 | 0.257 |
| Absolute change | –0.02 | 0.05 | 0.009 | 0.05 | 0.045 |
Values are %, unless otherwise indicated. Septal bounce is reported as absolute change in LV eccentricity index from end expiration to peak inspiration.
A, late-diastolic; D, diastolic; E, early diastolic; HV, hepatic vein; IVC, inferior vena cava; LV, left ventricle; MUL, mulibrey nanism; MV, mitral valve; PV, pulmonary vein; S, systolic; TV, tricuspid valve.
Figure 1Sample images of respiratory changes in (A, E, I) hepatic vein flow, (B, F, J) right ventricular inflow, and (C, G, K) outflow, (D, H, L) septal curvature (M-mode) in a (A-D) 3-year-old mulibrey nanism (MUL) patient without pericardiectomy; (E-H) a 10-year-old MUL patient with pericardiectomy performed 2 years earlier; and (I-L) a 3-year-old healthy control. Note (A) early expiratory flow reversals during atrial contraction in hepatic veins, (B) significant increase in right ventricular inflow, (C) minor increase in right ventricular outflow, as well as (D) septal shift during inspiration in MUL patient without pericardiectomy. Note (F) moderate increase in right ventricular inflow, (E) minor increase in right ventricular outflow during inspiration, but (E, H) absence of other respiratory changes in MUL patient with pericardiectomy. Note (J) minor inspiratory increase in right ventricular inflow, but (I, K, L) absence of other respiratory changes in healthy control subject.
Signs of heart failure, pericardial constriction, right ventricular (RV) and left ventricular (LV) systolic heart failure, and diastolic function among mulibrey nanism (MUL) patients with or without pericardiectomy, and among control subjects
| Sign | MUL patients with pericardiectomy (n = 5) | MUL patients, with no pericardiectomy (n = 18) | Control subjects (n = 23) | |
|---|---|---|---|---|
| Septal bounce > –0.05 | 3 | 16 | 4 | < 0.001 |
| HV A/D ratio in early expirium > 0.80 | 2 | 17 | 8 | 0.002 |
| Absent IVC collapse > 50% | 3 | 12 | 3 | 0.001 |
| Normal SepE’ > 9 cm/s | 2 | 16 | 23 | 0.049 |
| No SVC respiratory flow variation | 5 | 18 | 23 | NA |
| TAPSE/L < 0.20 | 2 | 0 | 0 | 0.489 |
| RVFWLS > –20% | 3 | 6 | 0 | 0.001 |
| TV S’ < 5 cm/s | 2 | 0 | 0 | 0.489 |
| RV-FAC < 30% | 0 | 0 | 0 | NA |
| Atrial area, cm2/m2 | 13.7 (5.6) | 11.1 (2.3) | 9.7 (1.1) | |
| Hepatic A-wave, cm/s | 30 (13) | 22 (7) | 18 (4) | |
| Tricuspid inflow E:A ratio | 1.4 (0.3) | 1.6 (0.5) | 2.1 (0.6) | |
| EF Simpson < 50% | 2 | 4 | 0 | 0.022 |
| MV S’ < 6 cm/s | 0 | 2 | 0 | 0.489 |
| MAPSE/L < 0.20 | 2 | 5 | 0 | 0.009 |
| LV-4GLS < –16% | 2 | 3 | 0 | 0.049 |
| Atrial volume, ml/m2 | 18.6 (7.3) | 21.9 (6.0) | 20.9 (3.9) | |
| Mitral inflow E:A ratio | 2.3 (0.5) | 2.3 (0.5) | 2.9 (1.1) | |
| Septal E:E’ ratio | 11.0 (3.6) | 8.3 (2.3) | 6.9 (1.5) | |
| Liver > 2 cm | 2 | 5 | 0 | 0.009 |
| Estimated jugular venous pressure, ≥ 10 mm Hg | 0 | 5 | 0 | 0.049 |
| Modified Ross Score > 1 | 1 | 9 | 0 | 0.001 |
| Plasma pro-BNP, ng/L | 301 (239–3264) | 168 (30–669) | NA |
Septal bounce was defined as > –0.05 absolute change in LV diastolic eccentricity index from end-expiration to peak inspiration. Superior vena cava (SVC) flow variation was assessed as variation in S/D wave velocities between end-expiration and peak inspiration. Absent inferior vena cava (IVC) collapse defined as failure to reach > 50% absolute decrease in IVC diameter from end-expiration to peak inspiration. GLS MUL patients vs control subjects compared with Fisher’s exact test. Mean (standard deviation) is reported for diastolic function parameters; median (range) is reported for plasma pro-hormone B-type natriuretic peptide (pro-BNP); and n is reported for all other variables.
E, early diastolic; E', E prime; EF, ejection fraction; GLS, global longitudinal strain; HV, hepatic vein; MAPSE, mitral annular plane systolic excursion; NA, not assessed. RV-FAC, RV fractional area change; RVFWLS, right ventricle free wall longitudinal strain; S', S prime; TAPSE, tricuspid annular plane systolic excursion.